Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023 - Seite 2
0
0
4 (8.7)
ORR% [95%CI]
37.5%
[26.0-50.6]
46.4%
[34.0-59.3]
48.2%
[35.7-61.0]
19.6%
[10.7-33.2]
Table 1: Efficacy results in SS patients (n=56)
____________________________________ |
1 includes patients not involved at baseline who progressed in the LN |
“The rapid and durable responses observed in the Phase 2 TELLOMAK trial which enrolled heavily pretreated patients, confirms that treatment with lacutamab achieves clinically meaningful outcomes for patients with Sézary Syndrome after at least two prior systemic therapies,” commented Dr. Sonia Quaratino, Chief Medical Officer of Innate Pharma. “Enrollment to TELLOMAK study is completed and long-term follow-up will provide more mature data on the key study endpoints in due course.”
Prof. Pierluigi Porcu, Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Sidney Kimmel Cancer Center, Jefferson Health, Philadelphia, and Principal Investigator in the TELLOMAK study, added: “Sézary Syndrome patients treated with more than two prior systemic therapies including mogamulizumab, represent a high unmet medical need population with poor quality of life. It is promising to see lacutamab achieving remarkable efficacy along with favorable safety in this heavily pre-treated population. We thank the investigators, clinical research coordinators, patients and caregivers involved in the TELLOMAK program.”
Lesen Sie auch
Innate Pharma will host a virtual KOL event, featuring Prof. Pierluigi Porcu, on lacutamab, highlighting results from ASH oral presentation on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM CET).
|
Virtual KOL Event Details |
Tuesday, December 12, 2023 at 7:00 AM PST (4:00PM CET) |
The live webcast will be available at the following link: |
Participants may also join via telephone using the following registration link: |